ID   BALL-1
AC   CVCL_1075
SY   Ball-1; Ball 1; BALL1; B-cell Acute Lymphoblastic Leukemia-1
DR   BTO; BTO:0001148
DR   CLO; CLO_0037300
DR   CLO; CLO_0051004
DR   CLO; CLO_0051005
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03471059
DR   BioSample; SAMN03472350
DR   cancercelllines; CVCL_1075
DR   CCRID; 5301HUM-KCB94007YJ
DR   Cell_Model_Passport; SIDM00287
DR   ChEMBL-Cells; CHEMBL3308839
DR   ChEMBL-Targets; CHEMBL2366269
DR   CLS; 305084
DR   Cosmic; 910705
DR   Cosmic; 919134
DR   Cosmic; 999755
DR   Cosmic; 999762
DR   Cosmic; 1150902
DR   Cosmic-CLP; 910705
DR   DepMap; ACH-002211
DR   DSMZ; ACC-742
DR   DSMZCellDive; ACC-742
DR   EGA; EGAS00001000978
DR   GDSC; 910705
DR   GEO; GSM827223
DR   GEO; GSM1669606
DR   IARC_TP53; 21184
DR   JCRB; JCRB0071
DR   KCB; KCB 94007YJ
DR   LINCS_LDP; LCL-1005
DR   PharmacoDB; BALL1_73_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1075
DR   PubChem_Cell_line; CVCL_1075
DR   RCB; RCB0256
DR   RCB; RCB1882
DR   TKG; TKG 0467
DR   Wikidata; Q54753112
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   DOI=10.11418/jtca1981.15.4_211;
RX   DOI=10.4044/joma1947.92.5-6_763;
RX   PubMed=195075;
RX   PubMed=197412;
RX   PubMed=2985879;
RX   PubMed=3159941;
RX   PubMed=3874327;
RX   PubMed=6582512;
RX   PubMed=8139288;
RX   PubMed=8156010;
RX   PubMed=8957066;
RX   PubMed=9290701;
RX   PubMed=9510473;
RX   PubMed=15901131;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Japanese.
CC   Doubling time: 80 hours (Note=In RPMI-1640 + 20% HCS), 66 hours (Note=In RPMI-1640 + 20% FCS) (PubMed=195075); ~48-72 hours (DSMZ=ACC-742).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp281Gly (c.842A>G); ClinVar=VCV000141141; Zygosity=Homozygous (PubMed=15901131; Cosmic-CLP).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=81.09%; East Asian, South=18.9%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: B-cell; CL=CL_0000236.
ST   Source(s): CCRID; Cosmic-CLP; DSMZ; JCRB; RCB; TKG
ST   Amelogenin: X (JCRB; TKG)
ST   Amelogenin: X,Y (CCRID; Cosmic-CLP; DSMZ; RCB)
ST   CSF1PO: 10,12
ST   D13S317: 9,12
ST   D16S539: 9
ST   D18S51: 12,13 (CCRID)
ST   D18S51: 13 (DSMZ)
ST   D19S433: 13,15.2 (CCRID)
ST   D19S433: 13,16 (DSMZ)
ST   D21S11: 30
ST   D2S1338: 19,22
ST   D3S1358: 16
ST   D5S818: 10,12,13 (RCB)
ST   D5S818: 10,13 (CCRID; Cosmic-CLP; DSMZ; JCRB; TKG)
ST   D7S820: 10,12
ST   D8S1179: 10,14
ST   FGA: 22,23
ST   Penta D: 9,10
ST   Penta E: 14,16
ST   TH01: 7,9
ST   TPOX: 8,11
ST   vWA: 14,18
DI   NCIt; C9143; Adult B acute lymphoblastic leukemia
DI   ORDO; Orphanet_99860; Precursor B-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   75Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 39
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   DOI=10.11418/jtca1981.15.4_211;
RA   Matsuo Y., Okochi A., Ariyasu T., Iimura E., Ohno T.;
RT   "Identification of cell lines with variable numbers of tandem repeat
RT   (VNTR) amplified by polymerase chain reaction.";
RL   Tissue Cult. Res. Commun. 15:211-219(1996).
//
RX   DOI=10.4044/joma1947.92.5-6_763;
RA   Nakamura K.;
RT   "Studies on human leukemic B-cell line, Part I. Establishment and
RT   characterization of human leukemic B-cell line (BALL-1).";
RL   Okayama Igakkai Zasshi 92:763-773(1980).
//
RX   PubMed=195075; DOI=10.1093/jnci/59.1.93;
RA   Hiraki S., Miyoshi I., Masuji H., Kubonishi I., Matsuda Y.;
RT   "Establishment of an Epstein-Barr virus-determined nuclear
RT   antigen-negative human B-cell line from acute lymphoblastic leukemia.";
RL   J. Natl. Cancer Inst. 59:93-94(1977).
//
RX   PubMed=197412; DOI=10.1038/267843a0;
RA   Miyoshi I., Hiraki S., Tsubota T., Kubonishi I., Matsuda Y.,
RA   Nakayama T., Kishimoto H., Kimura I., Masuji H.;
RT   "Human B cell, T cell and null cell leukaemic cell lines derived from
RT   acute lymphoblastic leukaemias.";
RL   Nature 267:843-844(1977).
//
RX   PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- 1.
RT   carboxylic esterase.";
RL   Leuk. Res. 9:209-229(1985).
//
RX   PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- III.
RT   Beta-hexosaminidase (E.C. 3.2.1.30).";
RL   Leuk. Res. 9:549-559(1985).
//
RX   PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid
RT   phosphatase.";
RL   Leuk. Res. 9:537-548(1985).
//
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
//
RX   PubMed=8139288; DOI=10.1016/0145-2126(94)90118-x;
RA   Sato S., Honma Y., Hozumi M., Hayashi Y., Matsuo Y., Shibata K.,
RA   Omura S., Hino K.-i., Tomoyasu S., Tsuruoka N.;
RT   "Effects of herbimycin A and its derivatives on growth and
RT   differentiation of Ph1-positive acute lymphoid leukemia cell lines.";
RL   Leuk. Res. 18:221-228(1994).
//
RX   PubMed=8156010; DOI=10.1159/000236736;
RA   Yoshida N., Ueno M., Saita N., Hirashima M.;
RT   "A B cell lymphoma line, BALL-1 stimulates T cells to produce a unique
RT   eosinophil chemotactic factor.";
RL   Int. Arch. Allergy Immunol. 104:9-11(1994).
//
RX   PubMed=8957066; DOI=10.1111/j.1349-7006.1996.tb03112.x;
RA   Kawasaki N., Matsuo Y., Yoshino T., Yanai H., Oka T., Teramoto N.,
RA   Liu C., Kondo E., Minowada J., Akagi T.;
RT   "Metastatic potential of lymphoma/leukemia cell lines in SCID mice is
RT   closely related to expression of CD44.";
RL   Jpn. J. Cancer Res. 87:1070-1077(1996).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x;
RA   Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y.,
RA   Hirai H.;
RT   "Frameshift mutations of the hMSH6 gene in human leukemia cell
RT   lines.";
RL   Jpn. J. Cancer Res. 89:33-39(1998).
//
RX   PubMed=15901131; DOI=10.1016/j.prp.2005.01.002;
RA   Murai Y., Hayashi S., Takahashi H., Tsuneyama K., Takano Y.;
RT   "Correlation between DNA alterations and p53 and p16 protein
RT   expression in cancer cell lines.";
RL   Pathol. Res. Pract. 201:109-115(2005).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//